Moderna, Inc. (MRNA)
| Market Cap | 13.12B |
| Revenue (ttm) | 3.24B |
| Net Income (ttm) | -3.56B |
| Shares Out | 384.82M |
| EPS (ttm) | -9.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 955,992 |
| Open | 36.15 |
| Previous Close | 33.73 |
| Day's Range | 33.90 - 34.32 |
| 52-Week Range | 29.25 - 170.47 |
| Beta | 1.59 |
| Analysts | Hold |
| Price Target | 59.65 (+74.98%) |
| Earnings Date | Feb 14, 2025 |
About MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vac... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price forecast is $59.65, which is an increase of 74.98% from the latest price.
News
Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges
On Friday, Moderna Inc. MRNA reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from EPS income of $0.55 a year ago.
A lot of concern around Moderna over next year or so, says Jefferies Michael Yee
Michael Yee, Jefferies senior analyst, joins 'Closing Bell Overtime' to talk Moderna Q4 results.
Moderna, Inc.: Working Hard But Competition Is Working Harder
MRNA's stock surged 4,211% during COVID-19 but has since plummeted to $31, reflecting a significant bubble and raising concerns about its future. Declining revenue and net income, driven by reduced CO...
Moderna (MRNA) Q4 2024 Earnings Call Transcript
Moderna (NASDAQ:MRNA) Q4 2024 Earnings Conference Call February 14, 2025 8:00 AM ET Company Participants Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive ...
Moderna has no 'visible path' to profitability, analyst says
Pharmaceutical giant Moderna (MRNA) released mixed fourth quarter results on Friday, posting revenue of $966 million (higher than the consensus estimate of $954 million) alongside a wider-than-expecte...
Moderna Posts Wider-Than-Expected Q4 Loss, 2025 Sales Guide Disappoints
Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for 2025 also came in below estimates.
MRNA Reiterates Guidance, Bird Flu Vaccine in Pipeline
Jenny Horne examines earnings figures from biotech giant Moderna (MRNA). The company reported a 4Q loss as it continues to reposition itself following monumental gains during the heights of the COVID-...
Moderna beats on revenue but loses more than expected as it scales down manufacturing
Moderna beat on fourth-quarter revenue but lost more than expected for the period, as the biotech company continues to slash costs and see lower demand for its Covid vaccine. It marks another quarter...
Moderna's wider-than-expected loss and soft guidance weigh on battered stock
COVID-19 vaccine sales topped consensus but RSV sales remain modest
Moderna posts bigger loss than expected as vaccine maker scales down manufacturing
Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down manufacturing amid weakening demand for its COVID-19 vaccine.
Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing...
Moderna Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Moderna, Inc. MRNA will release its fourth-quarter financial results, before the opening bell, on Friday, Feb. 14, 2025.
5 Struggling Stocks That Might Be Buys
Nike, Moderna, and Intel are among bargain stocks that might appeal to contrarian investors.
Vaccine, packaged food stocks fall as Kennedy moves closer to health secretary job
Shares of vaccine makers and packaged food companies fell on Tuesday after President Donald Trump's pick for U.S. health secretary, Robert F. Kennedy Jr., moved closer to the job after a favorable vot...
Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary
Shares of vaccine companies fell after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services to the full chamber.
Ethris Presents Positive Topline Phase 1 Data with mRNA Lead Candidate ETH47 for Uncontrolled Asthma
MUNICH, Germany--(BUSINESS WIRE)--Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced promising topline data from the completed Phase...
Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.
Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.
Moderna's stock is falling. Goldman Sachs says it's no longer a buy.
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech's second cut to product revenue guidance in six months.
Moderna to Report Fourth Quarter and Full Year 2024 Financial Results on Friday, February 14, 2025
CAMBRIDGE, MA / ACCESS Newswire / January 29, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 14, 2025 to re...
Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats CAMBRIDGE, MA / ACCESS Newswir...
A norovirus vaccine could be on the horizon as cases rise
Moderna is testing a norovirus vaccine in a phase three trial, with results available as soon as this year. Norovirus cases are on the rise this winter, with outbreaks already up more than 30% by Dece...
Vaxxas and CEPI Advance US$4.8 million (AU$7.2 million) Program for Needle-Free Thermostable mRNA Vaccines
CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today annou...
3-Stock Lunch: 3M, Moderna, & T-Mobile
Eva Ados, ERshares COO and chief investment strategist, joins CNBC's 'Power Lunch' to share outlooks on three stocks.
Why Is Moderna Stock Trading Higher On Tuesday?
Tuesday, Moderna Inc MRNA stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro.